This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Massardo, L. Articles by Rivero, S. Search for Related Content PubMed PubMed Citation Articles by Massardo, L. Articles by Rivero, S. Social Bookmarking                   What's this?

High-Dose Intravenous Methylprednisolone Therapy Associated with Osteonecrosis in Patients with Systemic Lupus Erythematosus

Servicio de Medicina, Hospital Dr Sótero del Rio, Servicio de Salud Metropolitano Sur-Oriente, Santiago

Sergio Jacobelli

Departamento de Inmunología Clínica y Reumatología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile

Mauricio Leissner

Departamento de Inmunología Clínica y Reumatología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile

Myriam González

Departamento de Inmunología Clínica y Reumatología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile

Luis Villarroel

Departamento de Inmunología Clínica y Reumatología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile

Santiago Rivero

Departamento de Inmunología Clínica y Reumatología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile

Osteonecrosis is related to the use of steroids in patients with systemic lupus erythematosus (SLE); its association with the use of 'pulses' of methylprednisolone (PMP) is not clear at present. In a retrospective analysis of 190 patients with SLE we found that 19% of 36 patients treated with PMP had osteonecrosis compared with 6% of 154 patients without that treatment (P < 0.04). Risk factors associated with osteonecrosis were PMP treatment, cushingoid appearance, steroid doses 40 mg/day during the first month of treatment, a ratio of steroid dose in grams/year 12, hematuria and proteinuria. In a stepwise regression model, when cushingoid appearance was excluded, PMP became the only significant factor (P = 0.045).

We conclude that osteonecrosis can be considered a long-term complication of PMP treatment in SLE patients.

Key Words: Osteonecrosis • Methylprednisolone • Systemic lupus erythematosus

Lupus, Vol. 1, No. 6, 401-405 (1992)
DOI: 10.1177/096120339200100610


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S.C.M.S. Fialho, E. Bonfa, L.F. Vitule, E. D'Amico, V. Caparbo, S. Gualandro, and R.M.R. Pereira Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus Lupus, April 1, 2007; 16(4): 239 - 244. [Abstract] [PDF]

				K Nagasawa, Y Tada, S Koarada, H Tsukamoto, T Horiuchi, S Yoshizawa, K Murai, A Ueda, Y Haruta, and A Ohta Prevention of steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus by anti-coagulant Lupus, June 1, 2006; 15(6): 354 - 357. [Abstract] [PDF]

				K Nagasawa, Y Tada, S Koarada, T Horiuchi, H Tsukamoto, K Murai, A Ueda, S Yoshizawa, and A Ohta Very early development of steroid-associated osteonecrosis of femoral head in systemic lupus erythematosus: prospective study by MRI Lupus, May 1, 2005; 14(5): 385 - 390. [Abstract] [PDF]

				A. Rascu, K. Manger, H-G. Kraetsch, J. Kalden, and B. Manger Review : Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation? Lupus, August 1, 1996; 5(4): 323 - 327. [Abstract] [PDF]

				L. Massardo and S. Jacobelli Occasional Series: Lupus Around the World The Chilean experience of systemic lupus erythematosus Lupus, June 1, 1996; 5(3): 175 - 177. [Abstract] [PDF]